Pharmaceutical company Teva has offered to buy fellow drug maker Mylan in a deal that could be worth $40 billion.
The Supreme Court of Canada has dismissed an appeal by French pharmaceutical company Sanofi in its patent dispute with Canadian generic drug maker Apotex.
Healthcare company Fresenius Kabi and India-based generic drug maker Claris Lifesciences have settled their patent dispute, ending pending litigation.
Mylan’s executive chairman Robert Coury has issued a statement confirming that his company and Teva will not merge.
Law firm Schiff Hardin has added a life sciences specialist as a partner in its intellectual property group.
Israeli pharmaceutical company Teva has, in one single filing, accused five generic drug makers of infringing a patent covering its blockbuster multiple sclerosis drug Copaxone.
The US Court of Appeals for the Federal Circuit has upheld the validity of four patents covering conjunctivitis treatment AzaSite.
Merck Sharp & Dohme has sued Apotex at the US District Court for the District of New Jersey for allegedly infringing a patent covering hay fever nasal spray Nasonex.
Forest Labs, a subsidiary of Actavis, has sued InvaGen for allegedly infringing four patents covering depression drug Viibryd, in what is the fifth related lawsuit.
A US appeals court has overturned a district court's decision to deny Apotex's request for a declaratory judgment that its proposed generic blood pressure drug would not infringe a patent owned by pharmaceutical company Daiichi Sankyo.